Patent ID: 11903971
Assignee: CELLPHIRE, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 16:
17. A method of treating a coagulopathy in a subject, wherein the coagulopathy is caused by von Willebrand disease, the method comprising administering intravenously to the subject in need thereof a therapeutically effective amount of a composition comprising freeze-dried platelet derivatives and an incubating agent comprising one or more salts, a buffer, and a cryoprotectant, wherein the composition is administered to the subject having von Willebrand disease, wherein the plasma of the subject is deficient in von Willebrand factor, and the freeze-dried platelet derivatives in the composition is an amount sufficient to form clots in plasma of the subject, wherein the therapeutically effective amount of the composition is at least 8.5×108 particles/kg of the subject, wherein the surface expression of CD42b on the freeze-dried platelet derivatives is between 25% and 50% of the surface expression of CD42b on normal platelets, and wherein the freeze-dried platelet derivatives are loaded with an anti-fibrinolytic agent selected from ε-aminocaproic acid, aprotinin, aminomethylbenzoic acid, tranexamic acid, and fibrinogen.